Search
Tresiba

Tresiba

insulin degludec

Manufacturer:

Novo Nordisk

Distributor:

Firma Chun Cheong
/
DKSH
Concise Prescribing Info
Contents
Insulin degludec
Indications/Uses
Improve glycemic control in DM patients ≥1 yr.
Click to view Tresiba detailed prescribing information
Dosage/Direction for Use
SC Insulin naïve patient Type 1 DM Recommended starting dose: Approx ⅓-½ of the total daily insulin dose. The remainder of the total daily insulin dose should be administered as a short-acting insulin & divided between each daily meal. Type 2 DM Recommended starting dose: 10 u once daily. Adult patient already on insulin therapy Start at the same unit dose as the total daily long or intermediate-acting insulin unit dose. Ped patient ≥1 yr already on insulin therapy Start at 80% of the total daily long or intermediate-acting insulin unit dose.
Click to view Tresiba detailed prescribing information
Overdosage
View Tresiba overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity. During episodes of hypoglycemia.
Click to view Tresiba detailed prescribing information
Special Precautions
Not recommended for the treatment of diabetic ketoacidosis. Risk of hypoglycemia w/ increased intensity of glycemic control, changes in meal pattern, changes in level of physical activity, or changes to co-administered medication. Patients w/ renal or hepatic impairment may be at higher risk of hypoglycemia. Monitor K levels in patients at risk for hypokalemia. Hyperglycemia or hypoglycemia w/ changes in insulin, manufacturer, type, or method of administration. Discontinue if hypersensitivity reactions occur. Use w/ caution in patients w/ visual impairment that may rely on audible clicks to dial the dose. Fluid retention & CHF w/ concomitant use of thiazolidinediones. May impair ability to drive & use machines. Pregnancy & lactation.
Click to view Tresiba detailed prescribing information
Adverse Reactions
Hypoglycemia. Nasopharyngitis, upper resp tract infection, headache. Type 1 DM: Sinusitis, gastroenteritis. Type 2 DM: Diarrhea.
Click to view Tresiba detailed prescribing information
Drug Interactions
Increased risk of hypoglycemia w/ antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (eg, octreotide), & sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors. Decreased blood glucose lowering effect w/ atypical antipsychotics (eg, olanzapine & clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, OCs, phenothiazines, progestogens (eg, in OCs), PIs, somatropin, sympathomimetic agents (eg, albuterol, epinephrine, terbutaline), & thyroid hormones. Possible increased or decreased blood glucose lowering effect w/ alcohol, β-blockers, clonidine, & lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia. Blunted signs & symptoms of hypoglycemia w/ β-blockers, clonidine, guanethidine, & reserpine.
Click to view Tresiba detailed prescribing information
Caution For Usage
For caution against possible variation of physical aspect of medicine... Click to view Tresiba detailed prescribing information
Storage
View Tresiba storage conditions for details to ensure optimal shelf-life.
Description
View Tresiba description for details of the chemical structure and excipients (inactive components).
Action
View Tresiba mechanism of action for pharmacodynamics and pharmacokinetics details.
ATC Classification
A10AE06 - insulin degludec ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.
Patient Counseling Information
View Tresiba patient counselling information
Presentation/Packing
Form
Tresiba FlexTouch (pre-filled pen) 100 U/mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in